Modified, cyclic dodecapeptide analog of neuropeptide Y is the smallest full agonist at the human Y<sub>2</sub> receptor
Beate Rist(University of California, San Francisco), Annette G. Beck‐Sickinger(Leipzig University of Applied Sciences), Léonardo Scapozza(University of Geneva), Oliver Zerbe(University of Zurich), R.L. McDonald(University of Leeds), H. Wieland(Pharmazeutische Fabrik Dr. Reckeweg (Germany)), Nikolaus Ingenhoven(ETH Zurich), Peter F. T. Vaughan(University of Leeds), Chris Peers(University of Leeds)
Cited by 42
Related Papers
XVI. International Union of Pharmacology Recommendations for the Nomenclature of Neuropeptide Y, Peptide YY, and Pancreatic Polypeptide Receptors
|Pharmacological Reviews|1998|893
GPR39 Signaling Is Stimulated by Zinc Ions But Not by Obestatin
|Endocrinology|2006|432
Herbal drugs and phytopharmaceuticals
|Pharmaceutica Acta Helvetiae|1995|415
The Concise Guide to PHARMACOLOGY 2023/24: G protein-coupled receptors
|British Journal of Pharmacology|2023|390
The first highly potent and selective non-peptide neuropeptide Y Y1 receptor antagonist: BIBP3226
|European Journal of Pharmacology|1994|374